NCT01644903|Recruiting
Proteogenomic Monitoring and Assessment of Liver Transplant Recipients
"Mini-Liver"
Loading search results
"Mini-Liver"
Sponsor study identifier
observational
1,000
1 country
1
Study Start
April 2010
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
December 2030
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
December 2031
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
This study is being done to test blood, urine and tissue samples to see if this can help decide if CKD (Chronic Kidney Disease), AR (Acute Rejection) and HCV (Hepatitis C Virus) can be identified in its early stages. CKD damage to the kidneys, AR and HCV all lower the body's ability to function properly. Early detection of these conditions could assist with successful treatment and possibly lead to less repeat organ transplants.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
December 2031
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
April 2010
Date type not reportedThis date has not been verified as actual or estimated.
July 17, 2012
Actual (reported)July 19, 2012
Actual (reported)December 2030
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
December 2031
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Proteogenomic Biomarkers for CKD, AR and HCV
To validate specific proteogenomic biomarker panels for CKD and AR (and HCV) in a prospective serial blood and urine monitoring study of liver transplant recipients
At time of liver biopsy
The intention of our biomarker panel is to be broadly applicable to all patients with liver transplant with the assumption that there are common underlying molecular mechanisms of CKD and AR (and HCV) that can be detected hopefully at early stages of disease. We therefore want to validate and test our biomarker panel in a broad collection of patient types.
Northwestern Memorial Hospital
Chicago, Illinois, 60611, United States
Urine Sample - One half cup of urine (100 mL) will be taken for research tests at each study visit. Blood Sample - About 1.5 tablespoons (20.5 mL) will be taken for research tests at each study visit. Liver Biopsy - A liver biopsy is a procedure to remove and examine a small piece of liver tissue. For this study, an extra tissue sample will possibly be taken during your biopsy. One additional needle pass may be made to collect the sample for this study.
Josh Levitsky, MD
Northwestern University
First Submitted
July 17, 2012
First Posted
July 19, 2012
Study Start
April 2010
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
December 2030
Safety and Effectiveness Using Pegasys and Copegus in Recipients of Liver Transplantation With Hepatitis C
Contact the study team to confirm eligibility.
Planned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
December 2031
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Last Updated
May 22, 2026
Record last verified: 2026-05
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: